Summary

Wani MC Taylor HL Wall ME Coggon P McPhail AT . Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971; 93: 2325–7.

Rowinsky EK Onetto N Canetta RM Arbuck SG . Taxol: The first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992; 19: 646–62.

National Cancer Institute clinical brochure: Taxol NSC 125973. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute, September 1983.

Grem JL Tutsch KD Simon KJ Alberti DB Willson JK Tormey DC . Phase I study of taxol administered as a short iv infusion daily for 5 days. Cancer Treat Rep 1987; 71: 1179–84.

Legha SS Tenney DM Krakoff IR . Phase I study of taxol using a 5-day intermittent schedule. J Clin Oncol 1986; 4: 762–6.

Kris MG O'Connell JP Gralla RJ Wertheim MS Parente RM Schiff PB . Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 1986; 70: 605–7.

Wiernik PH Schwartz EL Strauman JJ Dutcher JP Lipton RB Paietta E . Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987; 47: 2486–93.

Donehower RC Rowinsky EK Grochow LB Longnecker SM Ettinger DS . Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep 1987; 71: 1171–7.

Brown T Havlin K Weiss G Cagnola J Koeller J Kuhn J . A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 1991; 9: 1261–7.

Wiernik PH Schwartz EL Einzig A Strauman JJ Lipton RB Dutcher JP . Phase I trial of taxol given as a 24-hour infusion every 21 days: Responses observed in metastatic melanoma. J Clin Oncol 1987; 5: 1232–9.

Ohnuma T Zimet AS Coffey VA . Phase I study of taxol in a 24-h infusion schedule (abstract 662). Proc Am Assoc Cancer Res 1985; 26: 167.

Rowinsky EK Burke PJ Karp JE Tucker RW Ettinger DS Donehower RC . Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res 1989; 49: 4640–7.

Kingston DGI Samaranayake G Ivey CA . The chemistry of taxol, a clinically useful anticancer agent. J Nat Prod 1990; 53: 1–12.

National Cancer Institute clinical brochure: taxol IND 22850, NSC 125973. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute; revised, August 1990.

Hanauske A-R Degen D Hilsenbeck SG Bissery MC Von Hoff DD . Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anti-Cancer Drugs 1992; 3: 121–4.

Weiss RB Donehower RC Wiernik PH Ohnuma T Gralla RJ Trump DL Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8: 1263–8.

Sarosy G Kohn E Stone DA Rothenberg M Jacob J Adams DO Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 1992; 10: 1165–70.

Rowinsky EK Gilbert MR McGuire WP Grochow LB Forastiere AA Ettinger DJ Sequences of taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 1991; 9: 1692–1703.

Forastiere AA Rowinsky E Chaudry V Sartorious J Lubejko B Ettinger D Phase I trial of taxol (T) and cisplatin (C) + G-CSF in solid tumors (abstract 289). Proc Am Soc Clin Oncol 1992; 11: 117.

Holmes FA Walters R Valero V Thierault R Booser D Buzdar The M.D. Anderson experience with taxol in metastatic breast cancer. Second National Cancer Institute Workshop on Taxol and Taxus (abstract). Alexandria, VA, 1992.

Fisherman J McCabe M Hillig M Goldspiel B Cowan KH O'Shaughnessey JA Phase I study of taxol plus doxorubicin plus granulocyte colony stimulating factor (G-CSF) in patients with metastatic breast cancer. Second National Cancer Institute Workshop on Taxol and Taxus (abstract). Alexandria, VA, 1992.

Markman M Rowinsky E Hakes T Reichman B Jones W Lewis JL Phase I trial of intraperitoneal taxol: A Gynecologic Oncology Group Study. J Clin Oncol 1992; 10: 1485–91.

Rowinsky EK Citardi M Noe DA Donehower RC . Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol. In press.

Lassus M Scott D Leyland-Jones B . Allergic reactions (AR) associated with cremophor (C) containing antineoplastics (ANP) (abstract C-1042). Proc Am Soc Clin Oncol 1985; 4: 268.

Hayes FA Abromowitch M Green AA . Allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies. Cancer Treat Rep 1985; 69: 439–41.

Howrie DL Ptachcinski RJ Griffith BP Hardesty RJ Rosenthal JT Burckart GJ Anaphylactoid reactions associated with parenteral cyclosporine use: Possible role of Cremophor EL. Drug Intell Clin Pharm 1985; 19: 425–7.

Yahandra AM Adler KM Fisher GA Brophy NA Halsey J Hardy RI Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1992; 10: 1624–34.

Watkins J . Anaphylactoid reactions to I.V. substances. Br J Anaesth 1979; 51: 51–60.

Hüttel MS Olesen Schou A Stoffersen E . Complement-mediated reactions to diazepam with Cremophor as solvent (Stesolid MR). Br J Anaesth 1980; 52: 77–9.

Glen JB Davies GE Thomson DS Scarth SC Thompson AV . An animal model for the investigation of adverse responses to I.V. anaesthetic agents and their solvents. Br J Anaesth 1979; 51: 819–27.

Hacker M Koeferl M Hong CB Fagan MA . Cremophor® and Emulphor® induced alterations of serum lipids and lipoprotein electrophoretic patterns of dogs. Res Commun Chem Pathol Pharmacol 1981; 31: 119–28.

Beck WT . The cell biology of multiple drug resistance. Biochem Pharmacol 1987; 36: 2879–87.

Chervinsky DS Brecher ML Hoelcle MJ . Cremophor-EL reverses taxol cross resistance in murine C1300 multidrug resistant neuroblastoma cells (abstract 2851). Proc Am Assoc Cancer Res 1992; 33: 477.

Woodcock DM Linsenmeyer ME Chojnowski G Kriegler AB . Reversal of multidrug resistance by surfactants. Br J Cancer 1992; 66: 62–8.

Woodcock DM Jefferson S Linsenmeyer ME Crowther PJ Chojnowski GM Williams B Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 1990; 50: 4199–203.

Schuurhuis GJ Broxterman HJ Pinedo HM van Heijnigen THHM van Kalken CK Vermorken JB The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance. Br J Cancer 1990; 62: 591–4.

Dorr RT Alberts DS . Vinca alkaloid skin toxicity: Antidote and drug disposition studies in the mouse. J Natl Cancer Inst 1985; 74: 113–20.

Dorr RT Alberts DS . Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluents. Invest New Drugs 1983; 1: 151–9.

van der Valk P van Kalken CK Ketelaars H Broxterman HJ Scheffer G Kuiper CM Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Ann Oncol 1990; 1: 56–64.

Longnecker SM Donehower RC Cates AE Chen TL Brundratt RB Grochow LB High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 1987; 71: 53–9.

Rowinsky EK Cazenave LA Donehower RC . Taxol: A novel investigational antimicrotubule agent. J Natl Cancer Inst 1990; 82: 1247–59.

Monsarrat B Mariel E Cros S Gares M Guenard D Gueritte-Vogelein F Taxol metabolism: Isolation and identification of three major metabolites of taxol in rat bile. Drug Metab Dispos 1990; 18: 895–901.

Monsarrat B Wright M Dubois J Taxol metabolism in rat and human bile (abstract 258). Ann Oncol 1992; 3 (suppl 1):123.

Rizzo J Riley C Von Hoff D Kuhn J Phillips J Brown T . Analysis of anticancer drugs in biological fluids: Determination of taxol with application to clinical pharmacokinetics. J Pharm Biomed Anal 1990; 8: 159–64.

Rowinsky EK . The pharmacology of taxol. Second National Cancer Institute Workshop on Taxol and Taxus (abstract). Alexandria, VA, 1992.

Martoni A Zamagni C Gheka A Pannuti F . Antihistamines in the treatment of taxol-induced paroxystic pain syndrome. J Natl Cancer Inst 1993; 85: 676.

McGuire WP Rowinsky EK Rosenshein NB Grumbine FC Ettinger DS Armstrong DK Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273–9.

Thigpen T Blessing J Ball H Hummel S Barret R . Phase II trial of taxol as second-line therapy for ovarian carcinoma: A Gynecologic Oncology Group study (abstract 604). Proc Am Soc Clin Oncol 1990; 9: 156.

Einzig AI Wiernik PH Sasloff J Runowicz CD Goldberg GL . Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992; 10: 1748–53.

Sarosy G Kohn E Link C Davis P Ogniene F Goldspiel B Taxol dose intensification (D.I.) in patients with recurrent ovarian cancer (abstract 716). Proc Am Soc Clin Oncol 1992; 11: 226.

Holmes FA Walters RS Theriault RL Furman AD Newton LK Raber MN Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83: 1797–805.

Seidman A Reichman B Crown J Begg C Heelan R Hakes T . Activity of taxol with recombinant granulocyte colony stimulating factor (GCSF) as first chemotherapy (C) of patients (pts) with metastatic breast cancer (abstract 64). Proc Am Soc Clin Oncol 1992; 11: 59.

Norton L Seidman A Reichman B Crown JA Heelan R Hakes T Taxol plus recombinant human granulocyte colony stimulating factor as initial chemotherapy for metastatic breast cancer. Second National Cancer Institute Workshop on Taxol and Taxus (abstract). Alexandria, VA, September 22–23, 1992.

Wilson WH Kang YK Bryant G Berg S Stark-Vances V Bates S Phase I/II study of 96 hour infusional taxol in refractory lymphomas and breast cancer. Second National Cancer Institute Workshop on Taxol and Taxus (abstract). Alexandria, VA, 1992.

Murphy WK Fossella FV Winn RJ Shion DM Hynes H Gross HM Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993; 85: 384–8.

Chang AY Kim K Glick J Anderson T Karp D Johnson D Phase II study of taxol merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993; 85: 388–94.

Ettinger DS Finkelstein DM Sarma R Johnson DH . Phase II study of taxol in patients (PTS) with extensive-stage small cell lung cancer (SCLC): An Eastern Cooperative Oncology Group study (abstract 1094). Proc Am Soc Clin Oncol 1993; 12: 329.

Forastiere AA Neuberg D Taylor SG IV Phase II evaluation of taxol in advanced head and neck cancer. J Natl Cancer Inst In press.

Legha SS Ring S Papadopoulos N Raber M Benjamin RS . A phase II trial of taxol in metastatic melanoma. Cancer 1990; 65: 2478–81.

Einzig AI Hochster H Wiernik PH Trump DL Dutcher JP Garowski E A phase II study of taxol in patients with malignant melanoma. Invest New Drugs 1991; 9: 59–64.

Wiernik PH Einzig AI . Taxol in malignant melanoma. Second National Cancer Institute Workshop on Taxol and Taxus (abstract). Alexandria, VA, September 22–23, 1992.

Einzig AI Gorowski E Sasloff J Wiernik PH . Phase II trial of taxol in patients with metastatic renal cell carcinoma. Cancer Invest 1991; 9: 133–6.

Roth B Yeap B Wilding G Kasimis B McLeod D Loehrer X Taxol (NSC 125973) in advanced, hormone-refractory prostate cancer: An ECOG phase II trial (abstract 598). Proc Am Soc Clin Oncol 1992; 11: 196.

Rowinsky EK Donehower RC Jones RJ Tucker RW . Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 1988; 48: 4093–100.

LeBlanc GA Sundseth SS Weber GF Waxman DJ . Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. Cancer Res 1992; 52: 540–7.

Rowinsky EK Choudhry V Forastierra AA Sarterus SE Ettinger DS Grochow LB A Phase I and pharmacologic study of taxol and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting. J Clin Oncol 1993; 11: 2010–20.

McGuire WP Hoskins WJ Brady MF Kucera PR Look KY Partridge EE A Phase III trial comparing cisplatin/cytoxan and cis-platintaxol in adv anced ovarian cancer (abstract 808). Proc Am Soc Clin Oncol 1993; 12: 255.

Swenerton K Eisenhauer E ten Bokkel Huinink W Miles J Mangione C van den Burg M Taxol in relapsed ovarian cancer: High vs low dose and short vs long infusion: A European-Canadian study coordinated by the NCI Canada Clinical Trials Group (abstract 810). Am Soc Clin Oncol 1993; 12: 256.

Tishler RB Schiff PB Geard CR Hall EJ . Taxol: A novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992; 22: 613–7.

Slichenmyer W McGuire W Donehower R Bowling K Chen T-L Rowinski E Pharmacologic and toxic effects of various histamine-2 (H₂A) antagonists in taxol premedication regimens (abstract 440). Proc Am Soc Clin Oncol 1993; 12: 160.

Package insert. Taxol (paclitaxel) for injection concentrate. Princeton, NJ: Bristol-Myers Squibb, December 1992.

Adams JD Flora KP Goldspiel BR Wilson JW Arbuck S Finley R . Taxol (paclitaxel): A history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst Monogr In press.

Moorhatch P Chiou WL . Interactions between drugs and plastic intravenous fluid bags. Part II: Leaching of chemicals from bags containing various solvent media. Am J Hosp Pharm 1974; 31: 149–52.

Venkataramanan R Burckart GJ Ptachcinski RJ Blaha R Logue LW Bahnson A Leaching of diethylhexyl phthalate from polyvinyl chloride bags into intravenous cyclosporine solution. Am J Hosp Pharm 1986; 43: 2800–2.

Waugh WN Trissel LA Stella VJ . Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers. Am J Hosp Pharm 1991; 48: 1520–4.

Van Dooren AA . PVC as a pharmaceutical packaging material: A literature survey with special emphasis on plasticized PVC bags. Pharm Weekbl Sci 1991; 13: 109–18.

Ganning AE Brunk U Dallner G . Phthalate esters and their effect on the liver. Hepatology 1984; 4: 541–7.

Garvey LK Swenberg JA Hamm TE Popp A . Di(2-ethylhexyl)phthalate: Lack of initiating activity in the liver of female F-344 rats. Carcinogenesis 1987; 8: 285–90.

Kamrin MA Mayor GH . Diethyl phthalate: A perspective. J Clin Pharmacol 1991; 31: 484–9.

Smith A Thrussell IR Johnson GW . The prevention of plasticizer migration into nutritional emulsion mixtures by use of a novel container. Clin Nutr 1989; 8: 173–7.

Flaminio LM De Angelis L Ferazza M Marinovich M Galli G Galli CL . Leachability of a new plasticizer tri-(2-ethylhexyl)-trimellitate from haemodialysis tubing. Int J Artif Organs 1988; 11: 435–41.

Rathinam K Srivastava SP Seth PK . Hepatic studies of intraperitoneally administered tris(2-ethyl hexyl)trimellitate (TOTM) and di(2-ethyl hexyl)phthalate in rats. J Appl Toxicol 1990; 10: 39–41.

Goldspiel BR Kahler DR Kousicais AG Wilson WA Tollins AW O'Shaughnessey JA Paclitaxel administration using portable infusion pumps (letter). J Clin Oncol 1993; 11: 2287–8.

Data on file. Bristol-Myers Squibb Company, Princeton, NJ.

Trissel LA Bready BB . Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992; 49: 1716–9.

Trissel LA Martinez JF . Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993; 50: 300–4.

Fogel J Bokser A Goldspiel BR Chatterji DC Gallelli JF . Compatibility of admixtures of doxorubicin hydrochloride and taxol in 5% dextrose injection (abstract). Presented at the Eastern States Resident's Conference, Baltimore, MD: April 10, 1992.

Rowinsky EK McGuire WP Donehower RC . The current status of taxol. In: Hoskins WJ Perez CA Young RC , eds. Principles and practice of gynecologic oncology updates. Philadelphia: JB Lippincott; 1993: 1–16.

Rowinsky EK Eisenhauer EA Chaudhry V Arbuck SG . Clinical toxicities encountered with taxol. Semin Oncol 1993; 20 (suppl 2). In press.

Fisherman J McCabe M Hillig M Goldspiel B Cowan KH O'Shaughnessy JO . Phase I study of taxol and doxorubicin (DOX) with G-CSF in previously untreated metastatic breast cancer (MBC) (abstract 54). Proc Am Soc Clin Oncol 1992; 11: 57.

Lipton RB Apfel SC Dutcher JP Rosenberg R Kaplan J Berger A Taxol produces a predominantly sensory neuropathy. Neurology 1989; 39: 368–73.

Rowinsky EK Burke PJ Kapr JE Tucker RW Ettinger DS Donehower RC . Phase I and pharmacodynamic study of taxol in refractory acute leukemia. Cancer Res 1989; 49: 4640–7.

Apfel SC Lipton RB Arrezzo JC Kessler JA . Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol 1991; 29: 87–90.

Peterson ER Crain SM . Nerve growth factor attenuates neurotoxic effects of taxol on spinal cord-ganglion explants from fetal mice. Science 1982; 217: 377–9.

Brown T Havlin K Weiss G Cagnola J Koeller J Kuhn J A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 1991; 9: 1261–7.

Rowinsky EK McGuire WP Guarnieri T Fisherman JS Christian MC Donehower RC . Cardiac disturbances during the administration of taxol. J Clin Oncol 1991; 9: 1704–12.

Peereboom D Donehower RC Eisenhauer EA McGuire WP Onetto N Hubbard JL Successful re-treatment with taxol after major hypersensitivity reactions. J Clin Oncol (in press).

Holmes FA Frye D Valero V Walters RS Theriault RL Booser D Phase I study of paclitaxel (T) and doxorubicin (D) with G-CSF in patients (PT) without prior chemotherapy (CT) for metastatic breast cancer (MBC) (abstract 66). Proc Am Soc Clin Oncol 1992; 11: 60.

Ajani JA Dodd LG Daugherty K Warkentin D Ilson DH . Taxol-induced soft tissue injury secondary to extravasation: Characterization by histopathology and clinical course. J Natl Cancer Insti 1994; 86: 51–3.